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Associations between different bacteria and various tumours have been reported in patients for decades. Studies
involving characterisation of bacteria within tumour tissues have traditionally been in the context of tumourigenesis
as a result of bacterial presence within healthy tissues, and in general, dogma holds that such bacteria are causative
agents of malignancy (directly or indirectly). While evidence suggests that this may be the case for certain tumour
types and bacterial species, it is plausible that in many cases, clinical observations of bacteria within tumours arise
from spontaneous infection of established tumours. Indeed, growth of bacteria specifically within tumours following
deliberate systemic administration has been demonstrated for numerous bacterial species at preclinical and clinical
levels. We present the available data on links between bacteria and tumours, and propose that besides the few
instances in which pathogens are playing a pathogenic role in cancer, in many instances, the prevalent relationship
between solid tumours and bacteria is opportunistic rather than causative, and discuss opportunities for exploiting
tumour-specific bacterial growth for cancer treatment.Introduction
The development of cancer is associated with several
genetic and environmental factors. Furthermore there
has been an association between the development of
cancer and bacterial and viral infections for decades.
Several viruses can integrate into the human genome
and directly initiate tumourigenesis, such as human
papillomavirus (HPV) in cervical cancer and herpesvirus
in Kaposi’s sarcoma [1,2]. In other cases, the deve-
lopment of cancer is indirect, such as with Helicobacter
pylori, which contributes to both gastric cancer and
mucosa-associated lymphoid tissue (MALT) lymphoma
due to chronic inflammation caused by the bacteria
[3,4]. This notwithstanding, observations made in the
course of numerous studies have reported different indi-
genous bacterial species being isolated from infected
lesions in patients (Table 1) [5,6]. As early as 1868 Bush
reported 2 patients with sarcoma that had been infected
with Streptococcus and Coley also detected the presence
of S. pyogenes in a patient suffering from neck cancer
[7,8]. In 1907 Fibiger discovered that the parasitic nema-
tode (Spiroptera neoplastica) was associated with cancer* Correspondence: m.tangney@ucc.ie
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distribution, and reproduction in any mediumdevelopment in rats, while it was later found that the
development of cancer was associated with a vitamin A
deficiency he paved the way for future discoveries in
cancer causing bacteria and viruses [9]. In 1911 Francis
Peyton Rous was the first to discover that cancer could
be transmitted by a virus (later known as Rous sarcoma
virus), but it wasn’t until years later that his results were
accepted by the scientific community [10,11]. In 1926
Glover stated that certain bacteria were consistently
isolated from neoplastic tissue [12]. Furthermore bet-
ween the years of 1936–1955 several different publica-
tions all reported the presence of microbes in cancer
tissue [13-15]. More recently, it has been shown that
bacteria are naturally capable of homing to tumours
when systemically administered, resulting in high levels
of replication locally [16]. This was originally established
following IV administration of species of Clostridium,
and in more recent years with numerous bacterial
species, including, Salmonella, Bifidobacterium, Escherichia
coli, Vibrio cholerae and Listeria monocytogenes. Further-
more, various clinical trials have shown the ability of
different bacterial strains to home to and replicate speci-
fically within tumours [17-19].
The presence of bacteria within tumours could be due
to infection via the vasculature and their ability to
survive and grow due to the presence of nutrients withined Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Overview of bacteria identified in different
tumour types
Cancer Cancer role Reference
Lung cancer
Streptococcus mitis Prevalent [20]
Staphylococcus epidermis Prevalent [20]
Bacillus sp. Prevalent [20]
Mycoplasma sp. Causative [20,21]
Chlamydophila pneumonia Causative [22]
Pancreatic cancer
Robinsoniella peoriensis Prevalent [23]
Pedioccoccus acidilactici Prevalent [24]
Leuconostoc lactis Prevalent [24]
L. mesenteroides Prevalent [24]
Breast cancer
Staphylococcus epidermidis Prevalent [25]
Mycoplasma sp. Prevalent [21]
Oral cancer
Ralstonia insidiosa Prevalent [26]
Fusobacterium naviforme Prevalent [26]
Prevotella sp. Prevalent [26]
Gall-bladder carcinoma
Salmonella typhi Causative [27]
H. pylori Causative [28]
H. hepaticus Causative [28]
H. bilis Causative [29]
Pulmonary Mucosa-Associated lymphoid tissue (MALT) lymphoma
Chlamydia pneumonia Causative [30]
C. trachomatis Causative [30]
C. psittaci Causative [30]
Ocular Adenexa MALT lymphoma
C. psittaci Causative [31]
Ovarian cancer
Chlamydia trachomatis Prevalent [32]
Mycoplasma sp. Causative [33]
Mycoplasma sp. Causative [21]
Colorectal cancer
Streptococcus gallolyticus Causative [34]
Fusobacterium nucleatum Prevalent (?) [35,36]
F. necrophorum Prevalent [36,37]
F. mortiferum Prevalent [36]
F. perfoetens Prevalent [36]
Roseburia sp. Prevalent [37]
Faecalibacterium sp. Prevalent [37]
Escherichia coli Prevalent [38]
Citrobacter sp. Prevalent [38]
H. pylori Causative [39]
Mycoplasma sp. Prevalent [21]
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tumour growth (see below for proposed mechanism).
For example, sampling from humans has indicated that
bacterial translocation of Gastro-Intestinal Tract (GIT)-
associated bacteria may be a phenomenon that occurs in
healthy individuals representing a normal physiological
event without deleterious consequences [40]. It may be
that bacteria egress from the GIT at very low numbers,
and are normally quickly eliminated by the immune
system. However, the phenomenon of bacterial repli-
cation within tumours results in dramatic increases in
bacterial numbers within a confined region.
This review will focus on bacteria that have been iden-
tified within patient tumours and how they might be
used to aid in early detection (in the context of causative
agents) or treatment (subsequent infection) of cancers.
Bacteria as causative agents of cancer
There are several bacteria that have been associated or
defined as being causative agents of cancer (Table 1).
The most widely known of these bacteria would be
H. pylori which is the strongest known risk factor for
gastric cancer [41]. However only a small minority of
those infected develop gastric cancer or precancerous
gastric lesions. The reason for this is thought to be due
to several factors; strain biodiversity, geographical dis-
tribution and environmental factors. H. pylori is also
associated with an increased risk of pancreatic cancer,
thought to occur through pathophysiological actions of
the bacterium [41,42]. Recent data also support the
hypothesis that H. pylori is also associated with a slightly
increased risk of colorectal cancer [39].
Furthermore recent data promotes the paradigm that
gut bacteria can influence cancer risk in extra-intestinal
organs [43,44]. The means by which this occurs is not
fully elucidated, but is thought to involve both immunity
and metabolism as key factors in tumour promotion by
intestinal bacteria [45]. H. hepaticus is a murine entero-
hepatic bacterium that causes hepatitis and hepatocellu-
lar carcinoma (HCC) in some strains of mice [46]. A
recent study by Rogers demonstrated increased liver
tumours in mice colonized with H. hepaticus in the
lower bowels but without any requirements for hepatic
translocation or hepatitis induction [45]. This lead to the
conclusion, that H. hepaticus promotes liver cancer from
its endogenous niche in the lower bowels. Another study
using Apcmin/+Rag2−/− mice demonstrated an increased
risk of mammary cancer when infected with H. hepaticus,
further suggesting that gut microbes can promote extra-
intestinal cancer [44].
One of the bacterial agents that have been found to be
regularly associated with colorectal carcinoma (CRC) is
Streptococcus bovis/gallolyticus. S. bovis/gallolyticus is a
transient normal flora in the gut thought to be present
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association between S. bovis/gallolyticus and CRC is due
the increased load of S. bovis/gallolyticus in the colon,
which has been shown to be associated with inflamma-
tory bowel disease or malignant/premalignant lesions of
the tumour. From the research preformed to date it is
believed that S. bovis/gallolyticus association with CRC
seems to be of etiological nature and the proposed
carcinogenic potential of S. bovis/gallolyticus is most likely
a propagation factor for premalignant tissues. The early
detection of CRC via identification of S. bovis/gallolyticus
DNA or antibodies may be a potential screening method
for at high-risk groups [50].
C. pneumoniae is a Gram-negative bacillus and an
obligate intracellular parasite that causes respiratory
infections in over 50% of adults. The relationship bet-
ween C. pneumoniae and lung cancer has been studied
for over 10 years by clinical and laboratory research
methods but the results have been inconsistent. Recently
a meta-analysis approach was used to analyse previously
published data [51]. They concluded a dose–response
effect in which increasing lung cancer risk was associa-
ted with increasing IgA (serological criteria for chronic
infection) antibody titre, also suggested that higher titre
may be a better predictor of lung cancer risk than lower
antibody titres [51]. All these studies also indicated that
C. pneumoniae infection was associated with increased
risk of lung cancer in certain sub-groups such as young
individuals, men, former smokers and for squamous cell
carcinomas or small cell carcinomas [22,51-55].
The other side of the coin: opportunistic infections of
established tumours
While bacterial presence in certain tumours is associated
with the development of that cancer, in many cases,
bacteria present in tumours may reflect local infections
of existing malignant tissue [56]. Observations made in
the course of numerous studies have reported different
indigenous bacterial species being isolated from infected
lesions in patients (Table 1). After Bush’s report of
Streptococcus in sarcomas in 1868 [7], William Coley,
the “father of immunotherapy”, identified the presence
of S. pyogenes in soft tissue sarcoma, and was one of the
first to characterise concomitant infection of tumours
and how this could lead to remission of incurable neoplas-
tic malignancy [57,58]. In recent years there have been a
number of studies that show a correlation between bac-
terial infection and tumour regression. Ruckdeschel et al.
found that patients who developed empyema after lung
cancer had a significantly improved survival rate after
5 years compared with uninfected patients (50% v’s 18%)
[59]. Furthermore, two patients with malignant CNS
tumours unexpectedly regressed after infection. Of these
patients, one of the infections was viral in nature while thesecond was found to feature Corynebacterium hemolyticum
and Staphylococcus epidermidis. The patient survived for
9 years after his tumour was originally discovered [60]. A
recent study to determine the survival rate after infection in
glioblastoma multiforme patients demonstrated no survival
advantage in patients with post-operative infection but they
did find that the deep infection subgroup showed a trend
towards increased survival [61]. Bohman and colleagues
literature search revealed 9 patients with malignant in-
tracranial tumours who experienced prolonged survival
due to infection with a mean survival of 7.5-8 years and
no evidence of central nervous system recurrence upon
death. The majority of patients had infections with either
S. aureus or Enterobacter aerogens [61].
Mechanisms of bacterial replication within tumours
There are several proposed factors involved in how bac-
teria replicate and survive within tumours. Traditionally,
the main mechanism is thought to be due to the hypoxic
nature of many solid tumours, which results in low
oxygen levels compared with normal tissues, providing a
unique growth environment for anaerobic and facultative
anaerobic bacteria [62]. Other factors contributing to
bacterial replication in the tumour include the presence of
bacterial nutrients within the necrotic region such as
purines [63]. Furthermore, the involvement of bacterial
chemotaxis towards chemo-attractant compounds present
in necrotic regions (e.g. aspartate, serine, citrate, ribose or
galactose) produced by quiescent cancer cells has also
been suggested as a contributing factor [63].
As knowledge in the field grows, elements believed to
be key for tumour-specific bacterial replication include
aberrant neovasculature and local immune suppression
[63]. As tumours develop, they promote the construc-
tion of new blood vessels (neo-angiogenesis). However,
these newly formed vessels are highly disorganized with
incomplete endothelial linings and blind ends, resulting
in ‘leaky’ blood vessels and slow blood flow. This leaky
tumour vasculature may allow circulating bacteria to
enter tumour tissue, and embed locally (Figure 1) [63].
Furthermore, a variety of mechanisms are employed by
cancerous cells to avoid recognition by the immune
system resulting in insufficient immune activity within
tumours, potentially providing a refuge for bacteria to
evade immune clearance, not present elsewhere in the
body [64,65].
Systemic microbes: routes of infection
While blood is taken to be free of bacteria in healthy
individuals, it is plausible that establishment of a tumour
infection might occur even with extremely low numbers
of viable bacteria, given the phenomenon of tumour-
specific bacterial growth. This hypothesis suggests the
tumour providing a localized ‘amplified read-out’ for
Figure 1 Proposed mechanism of bacterial entry to and
proliferation within tumours. Tumour (pink/purple) development
leads to recruitment of new blood supply, involving disorganized
and leaky vasculature, permitting circulating bacteria (black) to enter
the tumour. Bacteria replicate primarily within hypoxic (pink) tumour
regions, which feature immune suppression, abundant nutrients and
low oxygen.
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Presence of bacteria in the blood stream may be due to
wound infection (e.g. post surgery), or bacterial trans-
location (BT) from the gastrointestinal tract (GIT).
GIT translocation
BT is the invasion of indigenous intestinal bacteria
through the gut mucosa into normal sterile tissue [66].
The means by which bacteria translocate is thought to
be by two distinct pathways of gastrointestinal perme-
ability: (1) transcellular through the enterocytes and (2)
paracellular using tight junctions [67]. There are also
thought to be two major methods by which bacterial
compounds gain access to systemic circulation; (1)
through the enteric venous system to the portal vein and
(2) following lymphatic drainage. After much analysis it is
thought that the lymphatic route is the primary pathway
of translocation [67]. Experimental and clinical studies
have detected both indigenous and non-indigenous
bacteria within the mesenteric lymph node (MLN). Somestudies have demonstrated that BT from the gut to the
MLN is quiet common, with it occurring in 4-59% of
patients [67]. Furthermore patients needing surgery for
abdominal infection fared much worse if the MLN was
infected with non-indigenous bacteria [67]. In normal
healthy individuals, the normal immune response will
destroy bacteria associated with BT by phagocytosis. How-
ever, immunocompromised individuals have a higher risk
of being affected by BT. Cannon et al., found that one of
the main underlying conditions increasing patients sus-
ceptibility to BT associated bacteraemia was cancer [68].
Penn and colleagues demonstrated an increased transloca-
tion from the GIT of S-180 tumour-bearing mice, leading
them to postulate that the immune deficiencies associated
with tumour growth may be adequate to allow the viable
bacteria to translocate from the GIT to the developing
tumour [69]. Our group has shown that oral adminis-
tration of non-pathogenic bacteria to mice results in
trafficking from the GIT with subsequent homing to and
replication specifically in tumours [70].
The ability of microorganisms to translocate, survive,
and proliferate in extra-intestinal tissues involves com-
plex interactions between the host defence mechanisms
and the bacterium’s ability to invade host tissues.
Although the importance of host immune function and
the bacterium’s intestinal population size have been
implicated as significant contributory factors, the precise
mechanisms involved remains unknown [5,66,69,71].
The oral microbiome
As described earlier, members of the oral microbiota
have been associated with pancreatic cancer [72,73].
Farrell and colleagues carried out microbial profiling
using the Human Oral Microbe Identification Microarray
(HOMIM) to compare the salivary microbiota between 10
pancreatic cancer patients and 10 normal matched healthy
controls [72]. In their study they found that the levels of
Neisseria elongata and Streptococcus mitis were decreased
in the cancer patients relative to healthy controls and the
level of Granulicaetella adiacens was increased in the
cancer patients. These results validate a link between N.
elongata and G. adiacens with periodontal disease, which
has been linked to an increased risk of pancreatic cancer
[72]. Farrell et al., postulated that as G. adiacens, an
opportunistic pathogen, may be associated with systemic
inflammation and an elevation in this bacteria could be
related to the decreased levels of S. mitis [72]. Further-
more S. mitis plays a protective role against the adhesion
of carcinogenic bacteria and the loss of S. mitis may
contribute to aggressive periodontitis. Whether the vari-
ation in oral bacteria in pancreatic cancer is causative
rather than reactive would have to be investigated further
to determine how local oral bacteria without entering the
blood stream could potentially cause systemic diseases,
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periodontal bacteria, such as Porphyromonas gingivalis it
is believed that lymph vessel openings trap bacteria en
route from the mouth to the blood stream and then carry
them to the vein of the venous angle near the supra-
clavicular area [74]. A previous study by Sakamoto and
colleagues analysed the regional lymph nodes of 30
patients with oral cancer [75]. A total of 153 lymph nodes
were harvested for microbiological examination. It was
found that viable bacteria were found in 45% of the lymph
nodes from 83% of patients. The cervical lymph nodes are
in contact with the lymphatic flow before returning to the
thoracic duct. The presence of viable bacteria, mainly oral
streptococcus, in these lymph nodes supports the hypoth-
esis of the association between oral mucosal damage and
bacterial invasion into general circulation [75]. Further-
more the anaerobic bacteria detected (Peptostreptococcus)
in the lymph nodes have been detected in gastrointestinal
tumour tissue suggesting that the oral mucosal defect
could promote translocation of anaerobes into the
regional nodes [75,76].
Farrell and colleagues then evaluated the specificity of
the microbial biomarkers against another HOMIM
microbial study that had been performed on lung cancer.
They observed that none of the bacterial biomarkers
validated in their study was significantly altered in the
microflora profile of lung cancer [72]. This validates that
the microbial biomarkers present in the saliva are
specific for pancreatic cancer.
Fusobacterium
A bacterium that of late has been linked with CRC is
Fusobacterium nucleatum [35,36]. F. nucleatum is an
invasive, adherent and pro-inflammatory anaerobe that
is commonly found in dental plaque and is well known
to be associated with periodontitis [77,78,79]. However,
Fusobacterium is also known to be a gut commensal
with probiotic features [79]. Castellarin and colleagues
analysed the RNA sequence of 11 matched pairs of
colorectal carcinoma and adjacent normal tissue and
found an over-representation of F. nucleatum [35]. They
postulated that the presence of the bacterium within the
tumour could just represent an prevalent infection at
an immunocompromised site or may be involved in
tumourigenesis [75].
Another study using a similar method identified the
presence of several Fusobacterium species in CRC, in
particular F. nucleatum, F. mortiferum and F. necrophrum
[36]. They believe that Fusobacterium may be following
the concept of the “alpha-bug” theory –where certain
members of a microbial community are capable of remo-
delling the microbiome as a whole to drive proinflam-
matory immune responses and colonic epithelial cell
transformation leading to cancer [36,80]. In addition,Fusobacterium has been associated with inflammatory
bowel disease (IBD), one of the three highest risk factors
for developing CRC [81]. Kostic and colleagues postulate
that Fusobacterium may contribute to tumourigenesis in a
limited subset of patients mainly thorough an inflamma-
tory mediated mechanism [36].
One interesting facet of F. nucleatum is that it is one
of the most prevalent species found in infections of the
amniotic fluid and the placenta leading to pre-term birth
[82,83]. There is also a correlation between pre-term
birth and periodontal disease. During periodontal infec-
tion the quantities of periodontal pathogens increases
dramatically leading to transient bacteraemia [84-86].
This can lead to selective colonization of undesired sites.
The ability of F. nucleatum to proliferate in the placenta
and eventually spread to the amniotic fluid and foetuses
may in part be due to local immunosuppression in
reproductive organs during pregnancy [87]. Furthermore
the slow blood flow rate and low shear force in the
venous sinuses of the placenta provides an opportunity
for F. nucleatum to adhere and invade the endothelial
cells [87]. As similar conditions occur within a tumour
this may be a reason why F. nucleatum has been iden-
tified within CRC. Even if there is no etiological link
between the bacterium and CRC the significant abun-
dance of Fusobacterium in CRC may be used for screen-
ing purpose [35].
Exploitation of opportunistic infective agents
The ideal anti-cancer therapy would selectively eradicate
tumours, whilst minimizing side effects to normal tissue.
Use of bacteria to specify therapeutic agents to tumours
presents an attractive strategy in this context, since we
and others have shown in mice that bacteria naturally
replicate specifically within tumours when systemically
administered [88]. Various preclinical trials have shown
the ability of different bacterial strains to traffic to
tumour sites, locally produce therapeutic agents, and
mediate highly effective and specific therapeutic res-
ponses. Bacterial cancer therapies to date have utilized
‘laboratory’ strains (e.g. Salmonella typhimurium or clos-
tridia), and while results in murine models have been
impressive, successes have failed to be replicated in
patients, with the inherent pathogenicity and immuno-
genicity of the bacteria employed outweighing thera-
peutic responses in patients.
Various preclinical and clinical trials have shown the
ability of different bacterial strains to selectively traffic
to tumour sites, and mediate highly effective and specific
therapeutic responses [63]. A wide range of gene therapy
strategies exists, aiming at inducing malignant cell death,
either directly (e.g. using ‘suicide’ genes) or indirectly,
such as cancer immunotherapy approaches based on
killing tumour cells through intervention of various
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nature of bacterial colonisation of tumours could be
exploited to aid in cancer treatment. In the case of non-
invasive bacteria, strains can be engineered to secrete
therapeutic proteins locally within the tumour environ-
ment, external to tumour cells [90]. This cell therapy
approach is suitable for indirectly acting therapeutic stra-
tegies such as anti-angiogenesis and immune therapy.
Angiogenesis is the formation of new capillary blood
vessels from existing microvessels [63]. The anti-
angiogenesis strategy seeks to prevent the formation
of new vessels. Gene-based anti-angiogenic therapy has
been used in conjunction with other approaches to
decrease angiogenesis. Bifidobacterial expression of
endostatin genes, an endogenous inhibitor of angiogen-
esis, have shown promise in pre-clinical trials [63]. In
addition Salmonella VPN2009 has been successful in medi-
ating anti-angiogenic therapy [63]. The immune therapy ap-
proach focuses on killing the tumour cell through direct or
indirect alteration of immune effector cells (i.e. CD8+, T cells
or NK cells). S. Typhimurium has been used in several mur-
ine trials examining immunotherapies, with significant
tumour reduction resulting from local bacterial expression
or tumour cell expression of the immune-stimulating mole-
cules IL-18, CCL21, LIGHT or Fas ligand [63]. Preclinical
studies have also used bifidobacteria in combination therapy
with cytokines such as granulocyte colony-stimulating factor
(GCSF), resulting in superior anti-tumour effects [63].
However, bacterial studies have largely focused on
delivery of genes for subsequent tumour cell expression
of anti-cancer agents utilizing pathogenic invasive
bacterial species. Invasive bacteria are capable of delive-
ring genes intracellularly with the aim of targeting
bactofection to tumours. Bactofection is bacterial-
mediated transfer of plasmid DNA to mammalian cells
and has shown potential as a method to express hetero-
logous proteins in different mammalian cells types
[91,92]. In bactofection the bacteria contain a plasmid-
based gene for transfer to the new host cells. Delivery of
genetic material is achieved through entry of the entire
bacterium into the target cells. Spontaneous or induced
bacterial lysis leads to release of the plasmid for future
eukaryotic cell expression. Various bacterial species
including Salmonella spp., L. monocytogenes, and E. coli
have been examined as bactofection vectors. Salmonella
is the most widely studied genus for bactofection with
numerous studies demonstrating therapeutic expression
and anti-tumour efficacy [63]. Preclinical trials utilising
various attenuated, replication incompetent strains of
salmonellae delivered by direct intratumoural or systemic
administration have achieved impressive anti-tumour
responses using a range of therapeutic approaches. The
mechanism of DNA transfer is at present poorly under-
stood for many species, and may depend on propertiesinherent to the bacteria and the cell type involved [93].
Invasive strains are pathogenic in nature and therefore
invade healthy tissue (liver, spleen, MLN etc.), and safety
concerns need to be addressed before such an approach
becomes applicable in humans [63].
Furthermore bacteria, which replicate within tumours,
can be engineered to express imaging agents, allowing
detection of the bacteria and the potential tumour site
[63]. Given the vital aspect of early detection for cancer
treatment the potential for tumour-specific bacteria in
diagnostic applications is attractive. If there is a defi-
nitive link between cancer development and bacterial
infection this can be used in developing new treatment
strategies for cancer. Furthermore microbes can affect
the metabolism of pharmaceutical agents including those
used to treat cancer. Therefore better knowledge of
microbe composition and metabolic activity could im-
prove therapeutic options.
Conclusion
The examples provided here are not comprehensive, but
are rather an indication of the alternative impacts
bacteria may have on different types of cancers. Screening
for bacteria present in cancer tissues of various histo-
logical types may open up new dimensions in our under-
standing of this relationship, and its importance, if any. As
high throughput deep sequencing technologies become
more available, mining for bacterial strains adapted to
survive within the tumour microenvironment will permit
dedicated studies on this phenomenon, perhaps even
leading to the characterisation of a potential ‘tumour
microbiome’, and may also advance the development of
live bacterial vectors for tumour-specific delivery of thera-
peutic agents.
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